Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 8
Submit an article Journal homepage
4,517
Views
31
CrossRef citations to date
0
Altmetric
Diabetes

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

Priscilla HollanderBaylor Endocrine Center, Dallas, TX, USA;
,
Julie HillMerck & Co. Inc., Kenilworth, NJ, USA;
,
Jeremy JohnsonMerck & Co. Inc., Kenilworth, NJ, USA;
,
Zhi Wei JiangMSD R&D (China) Co. Ltd, Beijing, China;
,
Gregory GolmMerck & Co. Inc., Kenilworth, NJ, USA;
,
Susan HuyckMerck & Co. Inc., Kenilworth, NJ, USA;
,
Steven G. TerraPfizer Inc., Andover, MA, USA;
,
James P. MancusoPfizer Inc., Groton, CT, USA;
,
Samuel S. EngelMerck & Co. Inc., Kenilworth, NJ, USA;
,
Brett Lauringformerly of Merck & Co. Inc., Kenilworth, NJ, USA; ;Currently at Takeda Pharmaceuticals, Cambridge, MA, USA
&
Jie LiuMerck & Co. Inc., Kenilworth, NJ, USA; Correspondence[email protected]
 show all
Pages 1335-1343 | Received 22 Oct 2018, Accepted 08 Feb 2019, Published online: 25 Mar 2019

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Paul Chan & Christopher Wai Kei Lam. (2022) The role of sulfonylureas in the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 23:3, pages 387-403.
Read now
Maka Siamashvili & Stephen N. Davis. (2021) Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes. Expert Opinion on Pharmacotherapy 22:16, pages 2181-2198.
Read now

Articles from other publishers (29)

Tyler Drake, Adrienne Landsteiner, Lisa Langsetmo, Roderick MacDonaldMaylen AnthonyCaleb KalinowskiKristen Ullman, Charles J. BillingtonAnjum Kaka, Shahnaz Sultan & Timothy J. Wilt. (2024) Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians. Annals of Internal Medicine 177:5, pages 618-632.
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner & Erhard Siegel. (2024) Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology & Diabetes.
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner & Erhard Siegel. (2024) Therapie des Typ-2-DiabetesTreatment of type 2 diabetes. Die Diabetologie 20:2, pages 212-260.
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner & Erhard Siegel. (2023) Therapie des Typ-2-DiabetesTreatment of type 2 diabetes. Die Diabetologie 19:5, pages 658-697.
Crossref
N. A. Petunina, E. V. Goncharova, M. Е. Теlnova, I. A. Kuzina, N. S. Martirosyan & A. Yu. Sochneva. (2023) Modern inhibitor of sodium-glucose cotransporter type 2 – ertugliflozin. Meditsinskiy sovet = Medical Council:6, pages 234-240.
Crossref
Pei-Chien Tsai, Wei-Jung Chuang, Albert Min-Shan Ko, Jui-Shuan Chen, Cheng-Hsun Chiu, Chun-Han Chen & Yung-Hsin Yeh. (2023) Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials. Cardiovascular Diabetology 22:1.
Crossref
Yuan‐Di Halvorsen, John Paul Lock, Juan P. Frias, Francisco José Tinahones, Dominik Dahl, Annie L. Conery & Mason W. Freeman. (2022) A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes, Obesity and Metabolism 25:1, pages 293-301.
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner & Erhard Siegel. (2022) Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology & Diabetes 130:S 01, pages S80-S112.
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner & Erhard Siegel. (2022) Therapie des Typ-2-DiabetesTreatment of type 2 diabetes. Die Diabetologie 18:5, pages 623-656.
Crossref
Bin Zhou, Yetan Shi, Rongrong Fu, Haixiang Ni, Lihu Gu, Yuexiu Si, Mengting Zhang, Ke Jiang, Jingyi Shen, Xiangyuan Li & Xing Sun. (2022) Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology 13.
Crossref
Fudan Zhang, Wenting Wang & Xu Hou. (2021) Effectiveness and safety of ertugliflozin for type 2 diabetes: A meta‐analysis of data from randomized controlled trials. Journal of Diabetes Investigation 13:3, pages 478-488.
Crossref
Li Liu, Fang-Hong Shi, Hua Xu, Yue Wu, Zhi-Chun Gu & Hou-Wen Lin. (2022) Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 12.
Crossref
Nanjing Shi, Yetan Shi, Jingsi Xu, Yuexiu Si, Tong Yang, Mengting Zhang, Derry Minyao Ng, Xiangyuan Li & Fei Xie. (2021) SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Public Health 9.
Crossref
Sonja G. Schütz, Abbey Dunn, Tiffany J. Braley, Bertram Pitt & Anita V. Shelgikar. (2021) New frontiers in pharmacologic obstructive sleep apnea treatment: A narrative review. Sleep Medicine Reviews 57, pages 101473.
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Hans-Martin Reuter & Erhard Siegel. (2021) Therapie des Typ-2-DiabetesTherapy of type 2 diabetes. Der Diabetologe 17:4, pages 422-447.
Crossref
Daryl J. Fediuk, Gianluca Nucci, Vikas K. Dawra, Ernesto Callegari, Susan Zhou, Cynthia J. Musante, Yali Liang, Kevin Sweeney & Vaishali Sahasrabudhe. (2021) End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor. CPT: Pharmacometrics & Systems Pharmacology 10:6, pages 529-542.
Crossref
Ernesto Callegari, Jian Lin, Susanna Tse, Theunis C. Goosen & Vaishali Sahasrabudhe. (2020) Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid. CPT: Pharmacometrics & Systems Pharmacology 10:2, pages 127-136.
Crossref
Desye Gebrie, Desalegn Getnet & Tsegahun Manyazewal. (2021) Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials. Scientific Reports 11:1.
Crossref
Jing Huang, Shuyuan Xiong, Shenglan Ding, Qingfeng Cheng & Zhiping Liu. (2020) Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research 2020, pages 1-13.
Crossref
Kimberly Lapham, Ernesto Callegari, Julie Cianfrogna, Jian Lin, Mark Niosi, Christine C. Orozco, Raman Sharma & Theunis C. Goosen. (2020) In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes. Drug Metabolism and Disposition 48:12, pages 1350-1363.
Crossref
Richard Pratley, Samuel Dagogo‐Jack, Bernard Charbonnel, Shrita Patel, Anne Hickman, Jie Liu, Lisa Tarasenko, Annpey Pong, Misoo C. Ellison, Susan Huyck, Ira Gantz & Steven G. Terra. (2020) Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies . Diabetes, Obesity and Metabolism 22:12, pages 2276-2286.
Crossref
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Hans-Martin Reuter & Erhard Siegel. (2020) Therapie des Typ-2-Diabetes. Diabetologie und Stoffwechsel 15:S 01, pages S65-S92.
Crossref
Silvina Gallo, Roberto A. Calle, Steven G. Terra, Annpey Pong, Lisa Tarasenko & Annaswamy Raji. (2020) Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Therapy 11:8, pages 1849-1860.
Crossref
Xiaodan Zhang, Zhen Zhong, Yanli Li & Wangen Li. (2020) Long‐term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Diabetes/Metabolism Research and Reviews 36:5.
Crossref
Shrita Patel, Anne Hickman, Robert Frederich, Susan Johnson, Susan Huyck, James P. Mancuso, Ira Gantz & Steven G. Terra. (2020) Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Therapy 11:6, pages 1347-1367.
Crossref
David Z. I. Cherney, Hiddo J. L. Heerspink, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Zhi J. Xu, Shrita Patel, Anne Hickman, James P. Mancuso, Ira Gantz & Steven G. Terra. (2020) Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia 63:6, pages 1128-1140.
Crossref
Steven B. Heymsfield, Annaswamy Raji, Silvina Gallo, Jie Liu, Annpey Pong, Hakima Hannachi & Steven G. Terra. (2020) Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus. Obesity 28:4, pages 724-732.
Crossref
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou & Nikolaos Tentolouris. (2019) SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. International Journal of Environmental Research and Public Health 16:16, pages 2965.
Crossref
Lesley J. Scott. (2019) Ertugliflozin in type 2 diabetes: a profile of its use. Drugs & Therapy Perspectives 35:8, pages 351-362.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.